Compare iShares Core MSCI EAFE ETF (IEFA) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs 10X Genomics Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $96.91, while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, iShares Core MSCI EAFE ETF nearer its low. Which is the better fit depends on your goals.
| IEFA | TXG | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $98.56 | $45.80 |
52-Week Low | $81.70 | $11.34 |
Market Cap | — | $5.48B |
Enterprise Value | — | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $95.57, down 0.71% with a bearish technical signal. The ETF focuses on developed international markets excluding North America, offering a competitive 0.07% expense ratio and 3.30% dividend yield. Recent performance shows 19.9% one-year gains, though trailing SPGM's 23.1%. Technical indicators show mixed signals with RSI in neutral territory and key support at $94.
Outlook remains cautious due to bearish technical momentum and developed market rate hikes. The fund provides diversification benefits against US concentration risk but faces currency volatility. Analyst sentiment is mixed, with some favoring broader international exposure through VXUS or IXUS for comprehensive global coverage.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
